Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Special Drug Use-Results Surveillance of Tafinlar/Mekinist in BRAF-Mutation-Positive Advanced/Recurrent Solid Tumors (Excluding Colorectal Cancer)
jRCT2031230623Recruiting
- Sponsor
- Novartis
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of dabrafenib + trametinib and trametinib in Nonhematologic neoplasms (2 arms), sponsored by Novartis. Started Jan 2024; status: recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031230623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230623.